Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)

NCT06536465 is registered in ClinicalTrials.gov with Recursion Pharmaceuticals Inc. as lead sponsor.

NCT NCT06536465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)
Lead sponsor
Recursion Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2024
Completion date
May 6, 2025
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent clostridioides difficile infection